Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous cytokine-induced killer cells (Guangxi Zhuang Autonomous Region People's Hospital)
- Development stage
- Unknown
- Lead developer
- Guangxi Zhuang Autonomous Region People's Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous cytokine-induced killer (CIK) cells are an adoptive cellular immunotherapy being investigated by the People's Hospital of Guangxi Zhuang Autonomous Region as a maintenance treatment for patients with small cell lung cancer (SCLC) who have completed first-line chemotherapy. CIK cells are a heterogeneous population of immune effector cells, predominantly CD3+ and CD56+ T cells, generated by the ex vivo expansion of peripheral blood mononuclear cells in the presence of interferon-gamma, anti-CD3 antibodies, and interleukin-2. These cells exhibit potent, non-major histocompatibility complex (MHC)-restricted cytotoxic activity against a wide range of tumor cells. The therapy aims to eradicate residual disease and prevent recurrence by enhancing the patient's systemic antitumor immunity and altering the interaction between the tumor and its host.
- Other names
- CIK cellsautologous CIK cellscytokine-induced killer cells
Beyond the preview
Go deeper on autologous cytokine-induced killer cells (Guangxi Zhuang Autonomous Region People's Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous cytokine-induced killer cells (Guangxi Zhuang Autonomous Region People's Hospital).